In a humanized mouse model of GBM, CD133 CAR-T cells demonstrated robust anti-tumor activity and significant therapeutic efficacy while not triggering acute systemic toxicity by intratumoral injection [147]. This evidence concerns the gene PROM1 and neoplasm.